Jeffrey Wolf, JD
Mr. Wolf has substantial experience in creating, financing, nurturing and growing new ventures based upon breakthrough research and technology. In 2008, he founded Heat Biologics, Inc. (now a wholly-owned subsidiary NightHawk Biosciences, Inc.) a publicly traded company engaged in the research and development of drugs focused on combating cancer and other diseases. He has served as the Chief Executive Officer of Heat Biologics since April 2010 and is the Chief Executive Officer and Board Chairman of NightHawk Biosciences.
Mr. Wolf is the founding partner of Seed-One Ventures, LLC, a venture capital group focused on seed-stage technology-based investments. Mr. Wolf has been a founder of Elusys Therapeutics, Inc., an antibody-based therapeutic company, Tyrx Pharma, Inc., a biopolymer-based company, Sensatex, Inc., a medical device company and Generation Mobile, Inc. a telecommunications company. Prior to founding Seed-One Ventures, Mr. Wolf served as the Managing Director of The Castle Group, Ltd., a biomedical venture capital firm. At both organizations, Mr. Wolf was responsible for supervising the formation and funding of new technology, biomedical, and service oriented ventures.
Mr. Wolf received an MBA from Stanford Business School, a JD from New York University School of Law and a BA with honors in Economics from the University of Chicago.